AI Insight
This cohort study examined the potential impact of implementing most-favoured-nation pricing for brand-name prescription drugs in US Medicare, which would tie US drug prices to those paid in other reference countries. The analysis projected that this pricing model would decrease net Medicare spending on brand-name medications. However, the estimated reductions in Medicare spending exceeded the total sales volume in the reference countries, indicating that pharmaceutical manufacturers would likely alter their pricing strategies in response, which could substantially diminish the actual savings achieved.
Why it matters
This research provides critical evidence for policymakers considering drug pricing reform in Medicare, demonstrating that while international reference pricing could reduce costs, manufacturers' strategic responses must be anticipated when projecting savings. The findings suggest that simple price-matching policies may not achieve their full theoretical savings potential without accounting for market dynamics and industry adaptation.
Understand the Science
Most-favoured-nation pricing for brand-name medicines in Medicare was projected to decrease net spending. Potential reductions in net Medicare spending would be substantially greater than sales in the reference countries, suggesting that shifts in manufacturer behaviour with model implementation could reduce possible savings.
Source: [Articles] Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study